SpectronRx Raises $85M to Scale Radiopharmaceutical Manufacturing Infrastructure

Healthcare doesn’t stall because of bad ideas. It stalls because the infrastructure can’t keep up with the ambition. SpectronRx just stepped into that gap and made it very clear they’re not here to wait their turn. SpectronRx locked in $85M in financing, with OrbiMed stepping in like a capital partner that knows exactly where the constraints live. And if you’ve been paying attention to radiopharmaceuticals, you already know the choke point isn’t imagination. It’s production. It’s scale. It’s getting isotopes where they need to be before physics says time’s up.

John Zehner, CEO, and Anwer Rizvi, President, aren’t new to this game. Decades deep in isotopes, cyclotrons, and nuclear pharmacy, they’ve seen hype cycles come and go while building the infrastructure everyone else eventually depends on. Alongside Peter Webner, COO, the operation feels less like a startup chasing headlines and more like a system designed to handle pressure when the spotlight hits.

The play here is simple, but not easy. Build an end to end radiopharmaceutical engine that covers isotope production, development, and GMP manufacturing without handing off risk at every stage. That’s how you turn complexity into velocity. That’s how you earn trust from biotech and pharma teams who don’t have time for weak links.

And then there’s the Grissom Aeroplex campus. 34 acres. 200,000 sq ft of GMP manufacturing. A roadmap that stretches past 1M sq ft. Over 300,000 patient doses already moving through the system annually. That’s not a vision deck. That’s throughput. That’s gravity.

OrbiMed didn’t show up for a science project. They showed up because demand for radioligand therapies and diagnostic isotopes is outpacing supply, and the companies that solve that imbalance don’t just participate in the market, they define it.

The takeaway is sharp if you’re building in complex industries. Flash gets attention, but infrastructure gets paid. SpectronRx didn’t chase noise. They built capacity, stayed close to the physics, and waited for the market to catch up. Now the market’s here. And suddenly everyone’s looking for a seat at a table that’s already been set.